Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 11, pp. 1493-1501
Open Access | Times Cited: 1162

Showing 1-25 of 1162 citing articles:

B cells are associated with survival and immunotherapy response in sarcoma
Florent Petitprez, Aurélien de Reyniès, Emily Z. Keung, et al.
Nature (2020) Vol. 577, Iss. 7791, pp. 556-560
Open Access | Times Cited: 1531
Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas

Cell (2017) Vol. 171, Iss. 4, pp. 950-965.e28
Open Access | Times Cited: 917
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
Yucai Wang, Shouhao Zhou, Fang Yang, et al.
JAMA Oncology (2019) Vol. 5, Iss. 7, pp. 1008-1008
Open Access | Times Cited: 681
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
Sandra P. D’Angelo, Michelle R. Mahoney, Brian Andrew Van Tine, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 3, pp. 416-426
Open Access | Times Cited: 631
Advancing therapy for osteosarcoma
Jonathan Gill, Richard Görlick
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 10, pp. 609-624
Closed Access | Times Cited: 554
Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine
Adriana C. Gamboa, Alessandro Gronchi, Kenneth Cardona
CA A Cancer Journal for Clinicians (2020) Vol. 70, Iss. 3, pp. 200-229
Open Access | Times Cited: 419
Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma
Yan Zhou, Yang Dong, Qingcheng Yang, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 409
New Horizons in the Treatment of Osteosarcoma
Paul S. Meltzer, Lee J. Helman
New England Journal of Medicine (2021) Vol. 385, Iss. 22, pp. 2066-2076
Closed Access | Times Cited: 397
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
Patrick Danaher, Sarah Warren, Rongze Lu, et al.
Journal for ImmunoTherapy of Cancer (2018) Vol. 6, Iss. 1
Open Access | Times Cited: 361
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
Breelyn A. Wilky, Matteo Trucco, Ty K. Subhawong, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 6, pp. 837-848
Closed Access | Times Cited: 316
Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy
Anastasia Constantinidou, Constantinos Alifieris, Dimitrios T. Trafalis
Pharmacology & Therapeutics (2018) Vol. 194, pp. 84-106
Closed Access | Times Cited: 292
Osteosarcoma
Hannah C. Beird, Stefan Bielack, Adrienne M. Flanagan, et al.
Nature Reviews Disease Primers (2022) Vol. 8, Iss. 1
Closed Access | Times Cited: 282
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
Florence Duffaud, Olivier Mir, Pascaline Boudou‐Rouquette, et al.
The Lancet Oncology (2018) Vol. 20, Iss. 1, pp. 120-133
Open Access | Times Cited: 271
Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies
Ingrid Lilienthal, Nikolas Herold
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 18, pp. 6885-6885
Open Access | Times Cited: 227
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Lara E. Davis, Vanessa Bolejack, Christopher W. Ryan, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 16, pp. 1424-1431
Open Access | Times Cited: 211
Osteosarcoma: Accelerating Progress Makes for a Hopeful Future
Amanda Saraf, Joelle M. Fenger, Ryan D. Roberts
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 198
Immuno-genomic landscape of osteosarcoma
Chia-Chin Wu, Hannah C. Beird, J. Andrew Livingston, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 185
Immune checkpoint inhibitors: The linchpins of modern immunotherapy
Breelyn A. Wilky
Immunological Reviews (2019) Vol. 290, Iss. 1, pp. 6-23
Closed Access | Times Cited: 177
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort
Antoîne Italiano, Alban Bessede, M. Pulido, et al.
Nature Medicine (2022) Vol. 28, Iss. 6, pp. 1199-1206
Closed Access | Times Cited: 176
Osteosarcoma: A comprehensive review of management and treatment strategies
Farzaneh Jafari, Saeed Javdansirat, Sarvin Sanaie, et al.
Annals of Diagnostic Pathology (2020) Vol. 49, pp. 151654-151654
Closed Access | Times Cited: 174
Osteosarcoma
Bree R. Eaton, Rudolf Schwarz, Ralph E. Vatner, et al.
Pediatric Blood & Cancer (2020) Vol. 68, Iss. S2
Open Access | Times Cited: 164
Angiosarcoma: a review of diagnosis and current treatment.
Jun Cao, Jiale Wang, Chiyu He, et al.
PubMed (2019) Vol. 9, Iss. 11, pp. 2303-2313
Closed Access | Times Cited: 163
Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution
Vaia Florou, Andrew E. Rosenberg, Eric Wieder, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 158
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab
Ciara M. Kelly, Cristina R. Antonescu, Timothy G. Bowler, et al.
JAMA Oncology (2020) Vol. 6, Iss. 3, pp. 402-402
Open Access | Times Cited: 156
Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade
Ravi Patel, Reinier Hernandez, Peter M. Carlson, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 602
Open Access | Times Cited: 155
Page 1 - Next Page

Scroll to top